Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Dentsply Sirona (XRAY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$10.65+9.46%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.51 → 1.47 EPS · FY ending Dec 31, 2027 · 12 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 12 to 12; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for XRAY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve liquidity and manage cash effectively | A supporting condition in Dentsply Sirona's published investment case. The stated target is maintain cash above $190 million. | Intact | cash falls below $190 million over next 4 quarters | Cash and cash equivalents: $239M FY2026-Q2; GAAP. Published target: maintain cash above $190 million. Target period is not explicitly aligned with this observation. Date unavailable239,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a recovery and execution story, not a steady compounder. The multi-year view is intact, with recent financial performance strong relative to peers, but management execution remains volatile and risk is elevated.
XRAY is described as cheap versus peers, while the model shows an expectations gap below its benchmark. The valuation signal has low confidence, and pricing is tagged as justified with no fragility flags, so the evidence does not point to a clear mismatch between expectations and fundamentals.
Near term, revenue pressure remains: quarterly revenue fell from $961 million in 2025-Q4 to $898 million in 2026-Q2, even as net income improved to $37 million from a loss in 2026-Q1. Management has reaffirmed its 2026 sales and adjusted EPS outlook, but the return-to-growth plan is making mixed progress, and earnings surprises have become less consistent.
The multi-year thesis depends on the return-to-growth plan restoring sales momentum while management maintains its 2026 outlook. A guidance cut or further weakening in jobs data would add risk; continued strength and higher guidance from healthcare peers could support the sector backdrop.
Over the next 1 to 3 years, XRAY’s improving earnings and peer-relative performance support an intact long-term thesis, but revenue trends and execution need close attention. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 3 supplied quarters. Management reported: “This action allows the redeployment of capital toward debt retirement and share repurchases, strengthening the balance sheet and accelerating long-term shareholder value creation.” “2026 Outlook The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50.” Operating cash flow was $40.000 million in 2026-Q1.
Deliver adjusted EPS of $1.40 to $1.50 in 2026 | A primary condition in Dentsply Sirona's published investment case. The stated target is >= $1.40 per share. | Intact | adjusted EPS falls below $1.40 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve 2026 revenue of $3.5B to $3.6B | A primary condition in Dentsply Sirona's published investment case. The stated target is >= $3.5 billion. | Intact | annual revenue falls below $3.5 billion in FY26 | Revenue: $898M FY2026-Q2; GAAP. Published target: >= $3.5 billion. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026898,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “"We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business.” “"During the quarter, we advanced our commercial restructuring and continued portfolio innovation, with early traction from distributor partners.” Revenue was $898.000 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.55 → $1.47 · observed estimates
$3.66B → $3.61B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $1.55 | $3,659,600,830 | 18 / 17 |
| 2026-07-25 | $1.55 | $3,659,600,830 | 18 / 17 |
| 2026-07-26 | $1.55 | $3,659,600,830 | 18 / 17 |
| 2026-07-27 | $1.55 | $3,659,600,830 | 18 / 17 |
| 2026-07-28 | $1.55 | $3,659,600,830 | 18 / 17 |
| 2026-07-29 | $1.55 | $3,657,324,611 | 12 / 14 |
| 2026-07-30 | $1.55 | $3,657,539,450 | 18 / 17 |
| 2026-07-31 | $1.55 | $3,657,539,450 | 18 / 17 |
| 2026-08-01 | $1.55 | $3,654,977,740 | 12 / 14 |
| 2026-08-02 | $1.55 | $3,657,539,450 | 18 / 17 |
| 2026-08-03 | $1.55 | $3,657,539,450 | 18 / 17 |
| 2026-08-04 | $1.55 | $3,657,539,450 | 18 / 17 |
| 2026-08-05 | $1.55 | $3,658,580,620 | 18 / 17 |
| 2026-08-06 | $1.55 | $3,654,977,740 | 12 / 14 |
| 2026-08-08 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-09 | $1.53 | $3,643,993,070 | 18 / 15 |
| 2026-08-10 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-12 | $1.52 | $3,634,254,060 | 18 / 17 |
| 2026-08-13 | $1.52 | $3,634,254,060 | 18 / 17 |
| 2026-08-14 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-15 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-16 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-17 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-18 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-19 | $1.55 | $3,656,185,347 | 12 / 14 |
| 2026-08-20 | $1.53 | $3,634,670,970 | 12 / 14 |
| 2026-08-21 | $1.53 | $3,634,670,970 | 12 / 14 |
| 2026-08-22 | $1.53 | $3,634,670,970 | 12 / 14 |
| 2026-08-23 | $1.52 | $3,634,670,970 | 12 / 14 |
| 2026-08-24 | $1.52 | $3,634,670,970 | 12 / 14 |
| 2026-08-25 | $1.52 | $3,634,670,970 | 12 / 14 |
| 2026-08-26 | $1.52 | $3,634,670,970 | 12 / 14 |
| 2026-08-27 | $1.52 | $3,634,670,970 | 12 / 14 |
| 2026-08-28 | $1.52 | $3,634,670,970 | 12 / 14 |
| 2026-08-29 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-08-30 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-08-31 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-01 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-02 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-03 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-04 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-05 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-06 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-07 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-08 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-09 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-10 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-11 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-12 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-13 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-14 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-15 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-16 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-17 | $1.52 | $3,634,671,989 | 12 / 14 |
| 2026-09-18 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-19 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-20 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-21 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-22 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-23 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-24 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-25 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-26 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-27 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-28 | $1.51 | $3,627,984,489 | 12 / 14 |
| 2026-09-29 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-09-30 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-01 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-02 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-03 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-04 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-05 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-06 | $1.51 | $3,627,603,992 | 12 / 13 |
| 2026-10-07 | $1.50 | $3,619,317,325 | 12 / 13 |
| 2026-10-08 | $1.50 | $3,619,317,325 | 12 / 13 |
| 2026-10-09 | $1.50 | $3,619,116,497 | 12 / 13 |
| 2026-10-10 | $1.50 | $3,619,116,497 | 12 / 13 |
| 2026-10-11 | $1.50 | $3,617,209,830 | 12 / 13 |
| 2026-10-12 | $1.50 | $3,617,209,830 | 12 / 13 |
| 2026-10-13 | $1.50 | $3,617,209,830 | 12 / 13 |
| 2026-10-14 | $1.50 | $3,617,209,830 | 12 / 13 |
| 2026-10-15 | $1.50 | $3,617,436,497 | 12 / 13 |
| 2026-10-16 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-17 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-18 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-19 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-20 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-21 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-22 | $1.50 | $3,616,169,830 | 12 / 13 |
| 2026-10-23 | $1.49 | $3,613,916,497 | 12 / 13 |
| 2026-10-24 | $1.49 | $3,613,916,497 | 12 / 13 |
| 2026-10-25 | $1.49 | $3,613,916,497 | 12 / 13 |
| 2026-10-26 | $1.49 | $3,613,916,497 | 12 / 13 |
| 2026-10-27 | $1.49 | $3,613,916,497 | 12 / 13 |
| 2026-10-28 | $1.48 | $3,609,514,866 | 12 / 13 |
| 2026-10-29 | $1.48 | $3,609,514,866 | 12 / 13 |
| 2026-10-30 | $1.48 | $3,609,514,866 | 12 / 13 |
| 2026-10-31 | $1.48 | $3,609,514,866 | 12 / 13 |
| 2026-11-01 | $1.48 | $3,609,514,866 | 12 / 13 |
| 2026-11-02 | $1.48 | $3,609,514,866 | 12 / 13 |
| 2026-11-03 | $1.47 | $3,609,514,866 | 12 / 13 |
| 2026-11-04 | $1.47 | $3,609,514,866 | 12 / 13 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 12 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 4 recorded
0 raises · 2 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.